Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 36
Filtrer
1.
Muscle Nerve ; 69(4): 422-427, 2024 Apr.
Article de Anglais | MEDLINE | ID: mdl-38334356

RÉSUMÉ

INTRODUCTION/AIMS: The clinical presentation of multifocal motor neuropathy (MMN) may mimic early amyotrophic lateral sclerosis (ALS) with predominant lower motor neuron (LMN) involvement, posing a diagnostic challenge. Both diseases have specific treatments and prognoses, highlighting the importance of early diagnosis. The aim of this study was to assess the diagnostic value of serum neurofilament light chain (NfL) in differentiating MMN from LMN dominant ALS. METHODS: NfL was measured in serum in n = 37 patients with MMN and n = 37 age- and sex-matched patients with LMN dominant ALS, to determine the diagnostic accuracy. Clinical and demographic data were obtained at the time of NfL sampling. RESULTS: Serum NfL concentration was significantly lower in MMN patients compared to ALS patients (mean 20.7 pg/mL vs. 59.4 pg/mL, p < .01). NfL demonstrated good diagnostic value in discriminating the two groups (AUC 0.985 [95% CI 0.963-1.000], sensitivity 94.6%, specificity 100%, cut-off 44.00 pg/mL). DISCUSSION: NfL could be a helpful tool in differentiating MMN from LMN dominant ALS in those patients in whom electrophysiological and clinical examinations remain inconclusive early in the diagnostic process.


Sujet(s)
Sclérose latérale amyotrophique , Polyneuropathies , Humains , Sclérose latérale amyotrophique/diagnostic , Marqueurs biologiques , Filaments intermédiaires , Pronostic , Polyneuropathies/diagnostic , Protéines neurofilamenteuses
2.
J Neurol ; 270(2): 909-916, 2023 Feb.
Article de Anglais | MEDLINE | ID: mdl-36308527

RÉSUMÉ

BACKGROUND: Congenital myasthenic syndromes (CMS) are a heterogeneous group of disorders caused by genetic defects resulting in impaired neuromuscular transmission. Although effective treatments are available, CMS is probably underdiagnosed, and systematic clinico-genetic investigations are warranted. METHODS: We used a nationwide approach to collect Austrian patients with genetically confirmed CMS. We provide a clinical and molecular characterization of this cohort and aimed to ascertain the current frequency of CMS in Austria. RESULTS: Twenty-eight cases with genetically confirmed CMS were identified, corresponding to an overall prevalence of 3.1 per million (95% CI 2.0-4.3) in Austria. The most frequent genetic etiology was CHRNE (n = 13), accounting for 46.4% of the cohort. Within this subgroup, the variant c.1327del, p.(Glu443Lysfs*64) was detected in nine individuals. Moreover, causative variants were found in DOK7 (n = 4), RAPSN (n = 3), COLQ (n = 2), GMPPB (n = 2), CHAT (n = 1), COL13A1 (n = 1), MUSK (n = 1) and AGRN (n = 1). Clinical onset within the first year of life was reported in one half of the patients. Across all subtypes, the most common symptoms were ptosis (85.7%), lower limb (67.9%), upper limb (60.7%) and facial weakness (60.7%). The majority of patients (96.4%) received specific treatment, including acetylcholinesterase inhibitors in 20, adrenergic agonists in 11 and 3,4-diaminopyridine in nine patients. CONCLUSIONS: Our study presents the first systematic characterization of individuals with CMS in Austria, providing prevalence estimates and genotype-phenotype correlations that may help to improve the diagnostic approach and patient management.


Sujet(s)
Syndromes myasthéniques congénitaux , Humains , Syndromes myasthéniques congénitaux/diagnostic , Syndromes myasthéniques congénitaux/épidémiologie , Syndromes myasthéniques congénitaux/génétique , Autriche/épidémiologie , Acetylcholinesterase/génétique , Résultat thérapeutique , Prévalence , Mutation
3.
Eur J Neurol ; 29(6): 1815-1824, 2022 06.
Article de Anglais | MEDLINE | ID: mdl-35239206

RÉSUMÉ

BACKGROUND AND PURPOSE: Hereditary myopathies with limb-girdle muscular weakness (LGW) are a genetically heterogeneous group of disorders, in which molecular diagnosis remains challenging. Our aim was to present a detailed clinical and genetic characterization of a large cohort of patients with LGW. METHODS: This nationwide cohort study included patients with LGW suspected to be associated with hereditary myopathies. Parameters associated with specific genetic aetiologies were evaluated, and we further assessed how they predicted the detection of causative variants by conducting genetic analyses. RESULTS: Molecular diagnoses were identified in 62.0% (75/121) of the cohort, with a higher proportion of patients diagnosed by next-generation sequencing (NGS) than by single-gene testing (77.3% vs. 22.7% of solved cases). The median (interquartile range) time from onset to genetic diagnosis was 8.9 (3.7-19.9) and 17.8 (7.9-27.8) years for single-gene testing and NGS, respectively. The most common diagnoses were myopathies associated with variants in CAPN3 (n = 9), FKRP (n = 9), ANO5 (n = 8), DYSF (n = 8) and SGCA (n = 5), which together accounted for 32.2% of the cohort. Younger age at disease onset (p = 0.043), >10× elevated creatine kinase activity levels (p = 0.024) and myopathic electromyography findings (p = 0.007) were significantly associated with the detection of causative variants. CONCLUSIONS: Our findings suggest that an earlier use of NGS in patients with LGW is needed to avoid long diagnostic delays. We further present parameters predictive of a molecular diagnosis that may help to select patients for genetic analyses, especially in centres with limited access to sequencing.


Sujet(s)
Maladies musculaires , Dystrophies musculaires des ceintures , Anoctamines/génétique , Autriche/épidémiologie , Études de cohortes , Humains , Faiblesse musculaire/génétique , Dystrophies musculaires des ceintures/diagnostic , Dystrophies musculaires des ceintures/génétique , Mutation , Pentosyltransferases/génétique
4.
J Clin Med ; 9(7)2020 Jul 14.
Article de Anglais | MEDLINE | ID: mdl-32674397

RÉSUMÉ

BACKGROUND: Hereditary transthyretin amyloidosis (hATTR) is an autosomal dominantly inherited disorder caused by an accumulation of amyloid fibrils in tissues due to mutations in the transthyretin (TTR) gene. The prevalence of hATTR is still unclear and likely underestimated in many countries. In order to apply new therapies in a targeted manner, early diagnosis and knowledge of phenotype-genotype correlations are mandatory. This study aimed to assess the prevalence and phenotypic spectrum of hATTR in Austria. METHODS: Within the period of 2014-2019, patients with ATTR-associated cardiomyopathy and/or unexplained progressive polyneuropathies were screened for mutations in the TTR gene. RESULTS: We identified 43 cases from 22 families carrying 10 different TTR missense mutations and confirmed two mutational hot spots at c.323A>G (p.His108Arg) and c.337G>C (p.Val113Leu). Two further patients with late onset ATTR carried TTR variants of unknown significance. The majority of patients initially presented with heart failure symptoms that were subsequently accompanied by progressive polyneuropathy in most cases. A total of 55% had a history of carpal tunnel syndrome before the onset of other organ manifestations. CONCLUSIONS: Our study underlined the relevance of hATTR in the pathogenesis of amyloid-driven cardiomyopathy and axonal polyneuropathy and indicated considerable genetic heterogeneity of this disease in the Austrian population. The estimated prevalence of hATTR in Austria based on this study is 1:200,000 but a potentially higher number of unknown cases must be taken into account. With respect to new therapeutic approaches, we strongly propose genetic testing of the TTR gene in an extended cohort of patients with unexplained heart failure and progressive polyneuropathy.

5.
ESC Heart Fail ; 7(4): 1900-1908, 2020 08.
Article de Anglais | MEDLINE | ID: mdl-32476276

RÉSUMÉ

AIMS: Cardiac involvement in myopathies that primarily affect the skeletal muscle is variable and may be subtle, necessitating sensitive diagnostic approaches. Here, we describe the prevalence of cardiac abnormalities in a cohort of patients with skeletal muscle disease presenting at a tertiary care neuromuscular centre. METHODS AND RESULTS: We systematically investigated patients with skeletal myopathies and comprehensively analysed their cardiac phenotype including 24 h electrocardiogram, echocardiography with strain analyses, contrast-enhanced cardiac magnetic resonance imaging, and, if at increased risk of coronary artery disease, computed tomography coronary angiography. We prospectively screened 91 patients with diverse skeletal myopathies and enrolled 73 patients. The most pronounced cardiac involvement was present in patients with dystrophic myopathies (cardiac abnormalities in 59% of patients). We analysed myotonic dystrophies (n = 29) in more detail and found prolonged QRS (99.4 ± 15.6 vs. 91.5 ± 10.3 ms; P = 0.027) and QTc times (441.1 ± 28.1 vs. 413.0 ± 23.3 ms; P < 0.001) and increased left atrial size (27.28 ± 3.9 vs. 25.0 ± 3.2 mm/m2 ; P = 0.021) when compared with healthy controls. Left ventricular systolic function was reduced (ejection fraction < 55%) in 31% of myotonic dystrophies, while only 4% had an ejection fraction < 50%. Apical peak systolic longitudinal strain was slightly reduced (P = 0.023). CONCLUSIONS: Screening for cardiac involvement in the skeletal muscle disease seems prudent particularly in patients with dystrophic myopathies. In the subset of myotonic dystrophy patients, QRS and QTc times as well as myocardial strain may be useful parameters. Their potential for predicting cardiac adverse events needs further evaluation.


Sujet(s)
Cardiopathies , Dystrophie myotonique , Études transversales , Échocardiographie , Électrocardiographie , Cardiopathies/complications , Cardiopathies/diagnostic , Cardiopathies/épidémiologie , Humains , Dystrophie myotonique/complications , Dystrophie myotonique/diagnostic , Dystrophie myotonique/épidémiologie
6.
J Neurol ; 266(3): 699-706, 2019 Mar.
Article de Anglais | MEDLINE | ID: mdl-30649616

RÉSUMÉ

BACKGROUND: Most patients with myasthenia gravis (MG) need long-term immunosuppressive therapy. However, conventional agents may have intolerable side effects, take too long or fail to achieve disease control. Rituximab (RTX) has emerged as an off-label treatment for refractory MG, but data on its use are still sparse. METHODS: We conducted a retrospective nationwide study contacting all Austrian neurologists to provide anonymized data of all adult MG patients treated with RTX and minimum follow-up of 3 months. The Myasthenia Gravis Foundation of America Postintervention Status scale was used to assess outcomes. RESULTS: 34 (60.7%) of a total of 56 patients were women. Median (IQR) age at diagnosis of MG and start of RTX were 41.5 (24.3; 65.8) and 47.5 (33; 71) years, respectively. Antibodies (ab) against acetylcholine receptor (AchR) and muscle-specific tyrosine kinase (MuSK) were present in 69.6% and 25% of patients, respectively (seronegative: 5.4%). Before RTX, 47 (83.9%) patients had had plasma exchange, immune adsorption or immunoglobulins. Three months after RTX, 14 of 53 (26.4%) patients were in remission. At last follow-up after a median of 20 (10; 53) months, remission was present in 42.9% of patients and another 25% had minimal manifestations. Remission was more frequent in patients with MuSK ab vs. those with AchR ab (71.4% vs. 35.9%, p = 0.022). RTX was safe. The presence of MuSK ab independently predicted remission after RTX. CONCLUSION: In this retrospective study on RTX for MG, the largest to date, RTX appeared safe, efficacious and fast acting. Benefit from RTX was greatest in MuSK ab + MG.


Sujet(s)
Facteurs immunologiques/usage thérapeutique , Myasthénie/traitement médicamenteux , Rituximab/usage thérapeutique , Résultat thérapeutique , Adulte , Sujet âgé , Autriche , Études de cohortes , Relation dose-effet des médicaments , Femelle , Humains , Modèles logistiques , Mâle , Adulte d'âge moyen , Récepteurs à activité tyrosine kinase/immunologie , Récepteurs cholinergiques/immunologie
7.
J Neurol ; 265(12): 2834-2840, 2018 Dec.
Article de Anglais | MEDLINE | ID: mdl-30259176

RÉSUMÉ

BACKGROUND AND OBJECTIVES: Multifocal motor neuropathy (MMN) is a rare neuropathy and detailed descriptions of larger patient cohorts are scarce. The objective of this study was to evaluate epidemiological, clinical, and laboratory features of MMN patients and their response to treatment in Austria and to compare these data with those from the literature. METHODS: Anonymized demographic and clinical data about MMN patients until 31.12.2017 were collected from registered Austrian neurologists. Exploratory statistics on clinical and laboratory features as well as treatment regimens and responses were performed. RESULTS: 57 Patients with MMN were identified, resulting in a prevalence of 0.65/100.000. Mean age of onset was 44.1 ± 13.1 years, the diagnostic delay 5.5 ± 8.4 years. In 77% of patients, symptom onset was in the upper limbs, and in 92%, it occurred in distal muscles. Proximal onset was never observed in the lower limbs. At the final follow-up, the majority of patients had atrophy (88%) in affected regions. Definite motor conduction blocks (CB) were found in 54 patients. Anti-GM1-IgM antibodies were present in 43%. Treatment with intravenous immunoglobulins improved muscle strength and INCAT score initially, but at last follow-up, both scores deteriorated to values before treatment. DISCUSSION: The findings of the present study corroborate the previous findings in MMN. Onset typically occurs in the upper limbs and mostly distal, CBs are found in the majority of cases, while anti-GM1-IgM antibodies are detected in only approximately 40%. Our study underlines that the initial good response to treatment fades over time.


Sujet(s)
Maladies du motoneurone/épidémiologie , Maladies du motoneurone/thérapie , Adolescent , Adulte , Âge de début , Sujet âgé , Autriche/épidémiologie , Autoanticorps/métabolisme , Femelle , Études de suivi , Ganglioside GM1/immunologie , Humains , Immunoglobuline M/métabolisme , Mâle , Adulte d'âge moyen , Maladies du motoneurone/physiopathologie , Neurologues , Prévalence , Enquêtes et questionnaires , Jeune adulte
9.
J Am Coll Cardiol ; 71(14): 1540-1549, 2018 04 10.
Article de Anglais | MEDLINE | ID: mdl-29622161

RÉSUMÉ

BACKGROUND: Cardiac troponins are often elevated in patients with skeletal muscle disease who have no evidence of cardiac disease. OBJECTIVES: The goal of this study was to characterize cardiac troponin concentrations in patients with myopathies and derive insights regarding the source of elevated troponin T measurements. METHODS: Cardiac troponin T (cTnT) and cardiac troponin I (cTnI) concentrations were determined by using high sensitivity assays in 74 patients with hereditary and acquired skeletal myopathies. Patients underwent comprehensive cardiac evaluation, including 12-lead electrocardiogram, 24-h electrocardiogram, cardiac magnetic resonance imaging, and coronary artery computed tomography. cTnT and cTnI protein expression was determined in skeletal muscle samples of 9 patients and in control tissues derived from autopsy using antibodies that are used in commercial assays. Relevant Western blot bands were subjected to liquid chromatography tandem mass spectrometry for protein identification. RESULTS: Levels of cTnT (median: 24 ng/l; interquartile range: 11 to 54 ng/l) were elevated (>14 ng/l) in 68.9% of patients; cTnI was elevated (>26 ng/l) in 4.1% of patients. Serum cTnT levels significantly correlated with creatine kinase and myoglobin (r = 0.679 and 0.786, respectively; both p < 0.001). Based on cTnT serial testing, 30.1% would have fulfilled current rule-in criteria for myocardial infarction. Noncoronary cardiac disease was present in 23%. Using cTnT antibodies, positive bands were found in both diseased and healthy skeletal muscle at molecular weights approximately 5 kDa below cTnT. Liquid chromatography tandem mass spectrometry identified the presence of skeletal troponin T isoforms in these bands. CONCLUSIONS: Measured cTnT concentrations were chronically elevated in the majority of patients with skeletal myopathies, whereas cTnI elevation was rare. Our data indicate that cross-reaction of the cTnT immunoassay with skeletal muscle troponin isoforms was the likely cause.


Sujet(s)
Muscles squelettiques/métabolisme , Maladies musculaires/sang , Myocarde/métabolisme , Troponine T/sang , Adulte , Marqueurs biologiques/sang , Technique de Western , Électrocardiographie , Femelle , Humains , Dosage immunologique , Imagerie par résonance magnétique , Mâle , Adulte d'âge moyen , Muscles squelettiques/imagerie diagnostique , Maladies musculaires/diagnostic , Tomodensitométrie
10.
Wien Med Wochenschr ; 167(15-16): 359-367, 2017 Nov.
Article de Allemand | MEDLINE | ID: mdl-28770409

RÉSUMÉ

Migraine is a complex, multifactorial, neurovascular disorder of the brain. Patients frequently have pericranial trigger points, but trigger point (TP) therapy for migraine has not yet been adequately studied. In contrast, lymphatic drainage (LD) has been studied in patients with migraine. The multifactorial origin of migraine suggests using a combination of approaches such as TP therapy and lymphatic drainage. The present study evaluated the effectiveness of TP therapy alone and in combination with LD in preventing migraine during treatment period and over an 8­week period after completion of treatment. A wait list control group served as a control group. Patients completed a headache calendar. The results of this pilot study suggest a beneficial effect for TP alone and TP combined with LD for migraine prophylaxis for 8 weeks after completion of treatment.


Sujet(s)
Drainage lymphatique manuel , Migraines/prévention et contrôle , Techniques de physiothérapie , Points de déclenchement , Adulte , Sujet âgé , Femelle , Humains , Mâle , Adulte d'âge moyen , Projets pilotes
11.
PLoS One ; 12(6): e0178371, 2017.
Article de Anglais | MEDLINE | ID: mdl-28575122

RÉSUMÉ

Several quantitative magnetic resonance imaging (MRI) techniques have been proposed to investigate microstructural tissue changes in amyotrophic lateral sclerosis (ALS) including diffusion tensor imaging (DTI), magnetization transfer imaging, and R2* mapping. Here, in this study, we compared these techniques with regard to their capability for detecting ALS related white matter (WM) changes in the brain and their association with clinical findings. We examined 27 ALS patients and 35 age-matched healthy controls. MRI was performed at 3T, after which we analyzed the diffusion properties, the magnetization transfer ratio (MTR), and the effective transversal relaxation rate R2* in 18 WM tracts that were obtained by a fully automated segmentation technique. ALS patients, especially with a bulbar onset, showed a bilateral increase in radial and mean diffusivity, as well as a reduction in fractional anisotropy of the corticospinal tract (CST), and diffusion changes in the parietal and temporal superior longitudinal fasciculus. A reduction of the MTR was found in both CSTs and an R2* reduction was seen only in the left CST. Tract-specific diffusion properties were not related to clinical status in a cross-sectional manner but demonstrated some association with disease progression over three subsequent months. DTI reveals more widespread WM tissue changes than MTR and R2*. These changes are not restricted to the CST, but affect also other WM tracts (especially in patients with bulbar onset), and are associated with the short term course of the disease.


Sujet(s)
Sclérose latérale amyotrophique/anatomopathologie , Tractus pyramidaux/anatomopathologie , Substance blanche/anatomopathologie , Adulte , Sujet âgé , Sclérose latérale amyotrophique/imagerie diagnostique , Anisotropie , Encéphale/imagerie diagnostique , Encéphale/anatomopathologie , Études transversales , Imagerie par résonance magnétique de diffusion , Imagerie par tenseur de diffusion , Femelle , Humains , Imagerie par résonance magnétique , Mâle , Adulte d'âge moyen , Imagerie multimodale , Études prospectives , Tractus pyramidaux/imagerie diagnostique , Substance blanche/imagerie diagnostique
13.
PLoS One ; 11(9): e0162288, 2016.
Article de Anglais | MEDLINE | ID: mdl-27662617

RÉSUMÉ

OBJECTIVES: To investigate the prognostic value of B-mode and Power Doppler (PD) ultrasound of the median nerve for the short- and long-term clinical outcomes of patients with carpal tunnel syndrome (CTS). METHODS: Prospective study of 135 patients with suspected CTS seen 3 times: at baseline, then at short-term (3 months) and long-term (15-36 months) follow-up. At baseline, the cross-sectional area (CSA) of the median nerve was measured with ultrasound at 4 levels on the forearm and wrist. PD signals were graded semi-quantitatively (0-3). Clinical outcomes were evaluated at each visit with the Boston Questionnaire (BQ) and the DASH Questionnaire, as well as visual analogue scales for the patient's assessment of pain (painVAS) and physician's global assessment (physVAS). The predictive values of baseline CSA and PD for clinical outcomes were determined with multivariate logistic regression models. RESULTS: Short-term and long-term follow-up data were available for 111 (82.2%) and 105 (77.8%) patients, respectively. There was a final diagnosis of CTS in 84 patients (125 wrists). Regression analysis revealed that the CSA, measured at the carpal tunnel inlet, predicted short-term clinical improvement according to BQ in CTS patients undergoing carpal tunnel surgery (OR 1.8, p = 0.05), but not in patients treated conservatively. Neither CSA nor PD assessments predicted short-term improvement of painVAS, physVAS or DASH, nor was any of the ultrasound parameters useful for the prediction of long-term clinical outcomes. CONCLUSIONS: Ultrasound assessment of the median nerve at the carpal tunnel inlet may predict short-term clinical improvement in CTS patients undergoing carpal tunnel release, but long-term outcomes are unrelated to ultrasound findings.

14.
Mult Scler ; 20(9): 1269-72, 2014 08.
Article de Anglais | MEDLINE | ID: mdl-24493472

RÉSUMÉ

The presence of erythroblasts in the peripheral blood is generally associated with severe underlying disorders. The anti-very late antigen-4 (anti-VLA-4) antibody natalizumab, which is approved for treatment of multiple sclerosis, mediates an increase in circulating haematopoietic stem cells and may also trigger erythroblastaemia. We investigated the prevalence of erythroblastaemia in sequential blood smears of 14 natalizumab-treated and 14 interferon-treated patients with multiple sclerosis. Erythroblastaemia was found in 13 natalizumab-treated subjects (93%), whereas all controls were negative (p<0.0001). Knowledge of this frequent side effect is crucial for the correct interpretation of blood smears in natalizumab-treated patients and to avoid unnecessary diagnostic procedures.


Sujet(s)
Érythroblastes/effets des médicaments et des substances chimiques , Hémopathies/induit chimiquement , Facteurs immunologiques/effets indésirables , Intégrine alpha4bêta1/antagonistes et inhibiteurs , Sclérose en plaques/traitement médicamenteux , Natalizumab/effets indésirables , Adulte , Autriche/épidémiologie , Études cas-témoins , Femelle , Hémopathies/sang , Hémopathies/diagnostic , Hémopathies/épidémiologie , Humains , Intégrine alpha4bêta1/immunologie , Mâle , Adulte d'âge moyen , Sclérose en plaques/diagnostic , Sclérose en plaques/épidémiologie , Sclérose en plaques/immunologie , Prévalence , Facteurs de risque , Résultat thérapeutique , Jeune adulte
16.
Joint Bone Spine ; 80(5): 503-7, 2013 Oct.
Article de Anglais | MEDLINE | ID: mdl-23237996

RÉSUMÉ

OBJECTIVES: Hirayama disease (HD) is a segmental cervical myelopathy which affects the C7-D1 myotomes and presents with unilateral or asymmetric upper limb weakness/wasting. The study aimed at systematically collecting cases of HD in Austria and at describing and discussing their presentation on clinical and instrumental investigations and at comparing them with cases reported from other countries. METHODS: Neurological Departments of secondary and tertiary centers and colleagues in outpatient units involved in the management of neuromuscular disorders in Austria were contacted and asked to provide standardised data about their HD cases. RESULTS: Altogether, nine unrelated cases were included. Mean age at onset was 18.3 years (range: 12.5-27 years). The female-to-male ratio was 0.29. Mean disease duration was 18.8 years. All patients presented with weakness or wasting of the distal upper limb muscles. A single arm (right: n=2, left: n=3) was affected in five cases and both arms in four. Six patients presented with tremor, two with fasciculations. EMG showed chronic neurogenic changes in all patients. Conventional cervical MRI was normal (n=1), showed focal atrophy (n=3), an intramedullary lesion (n=3), or abnormal straightening of the cervical spine (n=1). Dynamic MRI in a single patient showed anterior displacement of the dorsal dura, prominent epidural space, compressed cord over the posterior surface of vertebra C5-6, and a prominent crescent-shaped mass. Two patients received physiotherapy with beneficial effect in one. CONCLUSIONS: HD rarely also occurs in Austria, predominantly males are affected, and clinical presentation, course and outcome are not at variance from cases in other European or non-European countries.


Sujet(s)
Amyotrophies spinales infantiles/épidémiologie , Adolescent , Adulte , Sujet âgé , Autriche/épidémiologie , Enfant , Femelle , Humains , Mâle , Adulte d'âge moyen , Jeune adulte
17.
Ann Rheum Dis ; 72(12): 1934-9, 2013 Dec.
Article de Anglais | MEDLINE | ID: mdl-23212030

RÉSUMÉ

OBJECTIVE: To compare ultrasound measurement of median nerve cross-sectional area (CSA) at different anatomical landmarks and to assess the value of power Doppler signals within the median nerve for diagnosis of carpal tunnel syndrome (CTS). METHODS: A prospective study of 135 consecutive patients with suspected CTS undergoing two visits within 3 months. A final diagnosis of CTS was established by clinical and electrophysiological findings. CSA was sonographically measured at five different levels at forearm and wrist; and CSA wrist to forearm ratios or differences were calculated. Intraneural power Doppler signals were semiquantitatively graded. Diagnostic values of different ultrasound methods were compared by receiver operating characteristic curves using SPSS. RESULTS: CTS was diagnosed in 111 (45.5%) wrists; 84 (34.4%) had no CTS and 49 (20.1%) were possible CTS cases. Diagnostic values were comparable for all sonographic methods to determine median nerve swelling, with area under the curves ranging from 0.75 to 0.85. Thresholds of 9.8 and 13.8 mm(2) for the largest CSA of the median nerve yielded a sensitivity of 92% and a specificity of 92%. A power Doppler score of 2 or greater had a specificity of 90% for the diagnosis of CTS. Sonographic median nerve volumetry revealed a good reliability with an intraclass correlation coefficient of 0.90 (95% CI 0.79 to 0.95). CONCLUSIONS: Sonographic assessment of median nerve swelling and vascularity allows for a reliable diagnosis of CTS. Determination of CSA at its maximal shape offers an easily reproducible tool for CTS classification in daily clinical practice.


Sujet(s)
Syndrome du canal carpien/imagerie diagnostique , Nerf médian/imagerie diagnostique , Adulte , Sujet âgé , Syndrome du canal carpien/anatomopathologie , Syndrome du canal carpien/physiopathologie , Études cas-témoins , Femelle , Avant-bras/imagerie diagnostique , Avant-bras/innervation , Humains , Mâle , Nerf médian/vascularisation , Nerf médian/anatomopathologie , Nerf médian/physiopathologie , Adulte d'âge moyen , Conduction nerveuse , Études prospectives , Débit sanguin régional , Reproductibilité des résultats , Sensibilité et spécificité , Échographie-doppler/méthodes , Poignet/imagerie diagnostique , Poignet/innervation
18.
Circ Cardiovasc Genet ; 5(5): 490-502, 2012 Oct 01.
Article de Anglais | MEDLINE | ID: mdl-22923418

RÉSUMÉ

BACKGROUND: X-linked myopathy with postural muscle atrophy is a novel X-linked myopathy caused by mutations in the four-and-a-half LIM domain 1 gene (FHL1). Cardiac involvement was suspected in initial publications. We now systematically analyzed the association of the FHL1 genotype with the cardiac phenotype to establish a potential cardiac involvement in the disease. METHODS AND RESULTS: Seventeen male patients and 23 female mutation carriers were compared with healthy controls. Every patient underwent a comprehensive clinical and cardiovascular workup. ECG abnormalities occurred frequently in affected males and were less frequent in heterozygous females. Both male and female mutation carriers had increased myocardial mass (affected males=115.1±25.3 g/m(2); heterozygous females=95.1±19.6 g/m(2); controls=89.0±15.6 g/m(2) and 72.6±12.6 g/m(2); respectively) with increased wall thickness (typically midventricular and apical segments) mainly in affected males. Longitudinal systolic function was reduced in affected males (radial systolic strain: affected males=24.6±11.8%; male controls=43.2±14.8%; P=0.002). Diastolic dysfunction occurred in both affected males and heterozygous females. Cardiac MRI revealed a morphological hallmark of X-linked myopathy with postural muscle atrophy; a characteristic spongious structure and replacement fibrosis indicated by late enhancement could be detected in most affected males. X-linked myopathy with postural muscle atrophy was associated with reduced exercise capacity in affected males but not in heterozygous female mutation carriers. CONCLUSIONS: X-linked myopathy with postural muscle atrophy patients consistently showed electrical, functional, and characteristic morphological cardiac abnormalities that translate into reduced exercise capacity. Reduced systolic and diastolic function is associated with a novel type of spongious hypertrophic cardiomyopathy. An unexpected finding was that some cardiac abnormalities were also present in heterozygous female mutation carriers.


Sujet(s)
Cardiomyopathie hypertrophique/génétique , Protéines et peptides de signalisation intracellulaire/génétique , Protéines à domaine LIM/génétique , Protéines du muscle/génétique , Adulte , Sujet âgé , Séquence d'acides aminés , Pression sanguine/physiologie , Cardiomyopathie hypertrophique/physiopathologie , Électrocardiographie , Femelle , Gènes liés au chromosome X , Génotype , Hétérozygote , Humains , Protéines et peptides de signalisation intracellulaire/composition chimique , Protéines à domaine LIM/composition chimique , Imagerie par résonance magnétique , Mâle , Adulte d'âge moyen , Données de séquences moléculaires , Protéines du muscle/composition chimique , Dystrophie musculaire d'Emery-Dreifuss/physiopathologie , Mutation , Isoformes de protéines/composition chimique , Isoformes de protéines/génétique , Fonction ventriculaire , Dystrophie musculaire d'Emery-Dreifuss liée à l'X
19.
J Neurol Sci ; 318(1-2): 1-18, 2012 Jul 15.
Article de Anglais | MEDLINE | ID: mdl-22554690

RÉSUMÉ

Hereditary spastic paraplegia (SPG) is a clinically and genetically heterogeneous group of neurodegenerative disorders that are clinically characterised by progressive spasticity and weakness of the lower-limbs (pure SPG) and, majoritorian, additional more extensive neurological or non-neurological manifestations (complex or complicated SPG). Pure SPG is characterised by progressive spasticity and weakness of the lower-limbs, and occasionally sensory disturbances or bladder dysfunction. Complex SPGs additionally include cognitive impairment, dementia, epilepsy, extrapyramidal disturbances, cerebellar involvement, retinopathy, optic atrophy, deafness, polyneuropathy, or skin lesions in the absence of coexisting disorders. Nineteen SPGs follow an autosomal-dominant (AD-SPG), 27 an autosomal-recessive (AR-SPG), 5 X-linked (XL-SPG), and one a maternal trait of inheritance. SPGs are due to mutations in genes encoding for proteins involved in the maintenance of corticospinal tract neurons. Among the AD-SPGs, 40-45% of patients carry mutations in the SPAST-gene (SPG4) and 10% in the ATL1-gene (SPG3), while the other 9 genes are more rarely involved (NIPA1 (SPG6), KIAA0196 (SPG8), KIF5A (SPG10), RNT2 (SPG12), SPGD1 (SPG13), BSCL2 (SPG17), REEP1 (SPG31), ZFYVE27 (SPG33, debated), and SLC33A1 (SPG42, debated)). Among the AR-SPGs, ~20% of the patients carry mutations in the KIAA1840 (SPG11) gene whereas the 15 other genes are rarely mutated and account for SPGs in single families yet (CYP7B1 (SPG5), SPG7 (SPG7), ZFYVE26 (SPG15), ERLIN2 (SPG18), SPG20 (SPG20), ACP33 (SPG21), KIF1A (SPG30), FA2H (SPG35), NTE (SPG39), GJA12/GJC2 (SPG44), KIAA0415 (SPG48) and 4 genes encoding for the AP4-complex (SPG47)). Among the XL-SPGs, 3 causative genes have been identified (L1CAM (SPG1), PLP1 (SPG2), and SLC16A2 (SPG22)). The diagnosis of SPGs is based on clinical, instrumental and genetic investigations. Treatment is exclusively symptomatic.


Sujet(s)
Gènes dominants/génétique , Maladies génétiques liées au chromosome X/génétique , Modes de transmission héréditaire/génétique , Paraplégie spasmodique héréditaire/génétique , Cortex cérébral/métabolisme , Cortex cérébral/physiopathologie , Femelle , Humains , Mâle , Paraplégie spasmodique héréditaire/complications , Paraplégie spasmodique héréditaire/physiopathologie
20.
PLoS One ; 6(10): e26524, 2011.
Article de Anglais | MEDLINE | ID: mdl-22053194

RÉSUMÉ

Four-and-a-half LIM domain protein 1 isoform A (FHL1A) is predominantly expressed in skeletal and cardiac muscle. Mutations in the FHL1 gene are causative for several types of hereditary myopathies including X-linked myopathy with postural muscle atrophy (XMPMA). We here studied myoblasts from XMPMA patients. We found that functional FHL1A protein is completely absent in patient myoblasts. In parallel, expression of FHL1C is either unaffected or increased. Furthermore, a decreased proliferation rate of XMPMA myoblasts compared to controls was observed but an increased number of XMPMA myoblasts was found in the G(0)/G(1) phase. Furthermore, low expression of K(v1.5), a voltage-gated potassium channel known to alter myoblast proliferation during the G(1) phase and to control repolarization of action potential, was detected. In order to substantiate a possible relation between K(v1.5) and FHL1C, a pull-down assay was performed. A physical and direct interaction of both proteins was observed in vitro. In addition, confocal microscopy revealed substantial colocalization of FHL1C and K(v1.5) within atrial cells, supporting a possible interaction between both proteins in vivo. Two-electrode voltage clamp experiments demonstrated that coexpression of K(v1.5) with FHL1C in Xenopus laevis oocytes markedly reduced K(+) currents when compared to oocytes expressing K(v1.5) only. We here present the first evidence on a biological relevance of FHL1C.


Sujet(s)
Protéines et peptides de signalisation intracellulaire/métabolisme , Canal potassique Kv1.5/métabolisme , Protéines à domaine LIM/métabolisme , Protéines du muscle/métabolisme , Animaux , Technique de Western , Études cas-témoins , Cycle cellulaire , Lignée cellulaire , Prolifération cellulaire , Maladies génétiques liées au chromosome X/métabolisme , Maladies génétiques liées au chromosome X/anatomopathologie , Humains , Protéines et peptides de signalisation intracellulaire/génétique , Ouverture et fermeture des portes des canaux ioniques , Cinétique , Canal potassique Kv1.5/génétique , Protéines à domaine LIM/génétique , Mâle , Souris , Protéines du muscle/génétique , Amyotrophie/métabolisme , Amyotrophie/anatomopathologie , Protéines mutantes/métabolisme , Myoblastes/métabolisme , Myoblastes/anatomopathologie , Liaison aux protéines , Isoformes de protéines/génétique , Isoformes de protéines/métabolisme , Transport des protéines , RT-PCR , Fractions subcellulaires/métabolisme , Xenopus , Xenopus laevis
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE